Gujarat-based iodine-chemistry specialist making iodine derivatives, APIs and intermediates for pharma, agro and specialty-chemical customers, now expanding into contrast-media intermediates.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 1 | 1 | 1 | 5 | 14 | 16 | 16 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 45 | 94 | 99 | 105 |
| Borrowings | 9 | 11 | 23 | 29 | 11 | 52 | 0 | 0 |
| Other Liabilities | 9 | 17 | 23 | 19 | 15 | 37 | 75 | 54 |
| Total Liabilities | 22 | 34 | 59 | 71 | 85 | 198 | 190 | 175 |
| AssetsFixed Assets | 4 | 5 | 4 | 19 | 20 | 24 | 24 | 23 |
| CWIP | 0 | 4 | 8 | 0 | 0 | 1 | 5 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 29 | 29 | 29 |
| Other Assets | 18 | 26 | 46 | 52 | 66 | 144 | 132 | 114 |
| Total Assets | 22 | 34 | 59 | 71 | 85 | 198 | 190 | 175 |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 3 | 7 | 12 | 9 | -13 | -29 | 34 |
| Cash from Investing | -1 | -5 | -7 | -5 | -4 | -27 | -7 |
| Cash from Financing | -1 | -1 | -2 | -3 | 23 | 79 | -32 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — |
| Free Cash Flow | 2 | 2 | 7 | 1 | -17 | -38 | 24 |
| FCF Margin | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (18.5×) and current (15.7×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10% growth and a 16× exit, ₹210 only delivers your return if you pay ₹148. The price is currently baking in 17% growth.
EPS grows 10%/yr for 5 years, then fades to 6% over 2, exits at 16×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.0% | 14.70 |
| FY28 | 10.0% | 16.17 |
| FY29 | 10.0% | 17.78 |
| FY30 | 10.0% | 19.56 |
| FY31 | 10.0% | 21.52 |
| FY32 | 8.0% ·fade | 23.24 |
| FY33 | 6.0% ·fade | 24.63 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.